Compare CCNE & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCNE | OMER |
|---|---|---|
| Founded | 1865 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 736.3M | 628.9M |
| IPO Year | N/A | 2009 |
| Metric | CCNE | OMER |
|---|---|---|
| Price | $26.88 | $10.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $29.00 | $27.50 |
| AVG Volume (30 Days) | 101.9K | ★ 1.7M |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $227,923,000.00 | N/A |
| Revenue This Year | $13.84 | N/A |
| Revenue Next Year | $27.68 | N/A |
| P/E Ratio | $14.11 | ★ N/A |
| Revenue Growth | ★ 5.27 | N/A |
| 52 Week Low | $19.32 | $2.95 |
| 52 Week High | $28.30 | $13.60 |
| Indicator | CCNE | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 69.72 | 71.76 |
| Support Level | $25.78 | $9.31 |
| Resistance Level | $26.20 | $10.41 |
| Average True Range (ATR) | 0.63 | 0.80 |
| MACD | 0.21 | 0.17 |
| Stochastic Oscillator | 89.88 | 99.89 |
CNB Financial Corp is providing integrated financial solutions, which create value for both consumers and businesses. These solutions encompass deposit accounts, private banking, real estate, commercial, industrial, residential and consumer loans and lines of credit, credit cards, treasury services, online banking, mobile banking, merchant credit card processing, remote deposit and accounts receivable handling. It derives revenue through the operations as a full-service bank engaging in a full range of banking activities and services, including trust and wealth management services, for individual, business, governmental, and institutional customers. The company branch are located in Pennsylvania, Ohio, New York and Virginia.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.